Bristol BuSpar Share Halved By Generics; DuPont Deal Shows "Flexibility"
Executive Summary
Bristol-Myers Squibb's BuSpar (buspirone) market share has been cut by more than half since the launch of generic products at the end of March.
You may also be interested in...
AstraZeneca Crestor Copromotion Decision Coming: Nexium Has 6% Share
AstraZeneca expects to make a decision on whether to use a copromotion partner for the HMG-CoA reductase inhibitor Crestor (rosuvastatin) within "the next six to eight weeks," CFO Jonathan Symonds told the Goldman Sachs healthcare conference June 12 in Dana Point, Calif.
Bristol/DuPont Is Timely Deal: Will Disrupt Difficult 2002, Add To 2003
The Bristol/DuPont deal may offer Bristol-Myers Squibb a healthy dose of distraction heading through a difficult period of patent expirations.
Bristol Repositions Glucovance, Glucophage XR As Metformin Generics Loom
A money-back guarantee will be part of Bristol-Myers Squibb's repositioning efforts for the metformin line extensions Glucophage XR and Glucovance.